Skip to main content

Home/ Groups/ OARS funding Cancer
MiamiOH OARS

Fellowships | UICC - 0 views

  •  
    Through its fellowship programme, UICC aims to support health workers and cancer professionals focussing on cancer control, including cancer prevention, early detection, epidemiology, implementation and translational research, cancer treatment (surgery, radio- and chemotherapy), multidisciplinary patient care, rehabilitation, survivorship and palliative care. In 2018 there are 3 programmes available, the UICC Technical Fellowships (UICC-TF)  which provides the learning of new knowledge and skills in cancer control through a one month visit to an institution abroad, the YY study grants allow established cancer professionals to visit an institution abroad for 3 months to foster collaboration and knowledge sharing, and Bourses pour l'Afrique Francophone for cancer professionals in Francophone Africa.
MiamiOH OARS

The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) - 0 views

  •  
    The purpose of the NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) is to encourage and retain outstanding graduate students recognized by their institutions for their high potential and strong interest in pursuing careers as independent cancer researchers. The award will facilitate the transition of talented graduate students into successful cancer research postdoctoral appointments, and provide opportunities for career development activities relevant to their long-term career goals of becoming independent cancer researchers.
MiamiOH OARS

Cancer Prevention Clinical Trials Network (CP-CTNet): Data Management, Auditing, and Co... - 0 views

  •  
    This Funding Opportunity Announcement (FOA) is a part of the National Cancer Institute (NCI) initiative intended to support Cancer Prevention Clinical Trials Network (CP-CTNet). The goals for the CP-CTNet include: Design and conduct early phase clinical trials to assess the safety, tolerability, and cancer preventive potential of agents and interventions of varying classes, many of which target molecules or processes known to be important during carcinogenesis. These trials include phase 0 (microdosing), phase I (dose-finding), and phase II (preliminary efficacy) clinical trials; Characterization of the effects of these agents and interventions on their molecular targets, as well as on other biological events associated with cancer development (such as cell proliferation, apoptosis, growth factor expression, oncogene expression, immune response) and correlation of these effects with clinical endpoints. Development of further scientific insights into the mechanisms of cancer prevention by the agents examined, including the development of novel potential markers as determinants of response.
MiamiOH OARS

Cancer Prevention Clinical Trials Network (CP-CTNet): Data Management, Auditing, and Co... - 0 views

  •  
    Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) proposes and will support the Cancer Prevention Clinical Trials Network (CP-CTNet), for which the goals are as follows:

    Design and conduct of early phase clinical trials to assess the safety, tolerability, and cancer preventive potential of agents and interventions of varying classes, many of which target molecules or processes known to be important during carcinogenesis. These trials include phase 0 (micro-dosing), phase I (dose-finding), and phase II (preliminary efficacy) clinical trials.

    Characterization of the effects of these agents and interventions on their molecular targets, as well as on other biological events associated with cancer development (such as cell proliferation, apoptosis, growth factor expression, oncogene expression, immune response) and correlation of these effects with clinical endpoints.

    Development of further scientific insights into the mechanisms of cancer prevention by the agents examined, including the development of novel potential markers as determinants of response.
MiamiOH OARS

Communication and Decision Making for Individuals with Inherited Cancer Syndromes (U01 ... - 0 views

  •  
    The purpose of this FOA is to develop, test, and evaluate interventions and implementation approaches, or adapt existing approaches, to improve patient/provider/family risk communication and decision making for individuals and families with an inherited susceptibility to cancer.
MiamiOH OARS

Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium (U54 Clinical Trial Not A... - 0 views

  •  
    The purpose of this FOA is to promote research on the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation E. Intensify research on the major drivers of childhood cancers: Improve our understanding of fusion oncoproteins in pediatric cancer and use new preclinical models to develop inhibitors that target them. The goal of this FOA is to establish a consortium of collaborating research teams to advance our understanding of the biology and mechanisms of action of fusion oncoproteins in pediatric cancers, and to apply this knowledge towards developing targeted therapeutic approaches.
MiamiOH OARS

Quantitative Imaging Tools and Methods for Cancer Response Assessment (R01 Clinical Tri... - 0 views

  •  
    This purpose of this Funding Opportunity Announcement (FOA) is to provide a mechanism of support to research organizations interested in clinically translating already optimized quantitative imaging software tools capable of measuring or predicting the response of cancer to clinical therapies, or in translating imaging software tools for planning and validating radiation therapy treatment strategies in clinical trials. The quantitative software tools must have been developed and optimized during a performance period in the Quantitative Imaging Network (QIN) or under other separate funding. The proposed research effort should be an extension of the research that successfully completed the tasks of developing and optimizing the chosen software tools or data collection methods intended to facilitate clinical decision making during clinical trials. This FOA is intended to support the efforts of validating those software tools in prospective multisite clinical trials to test software tool performance and to demonstrate that the software tool can be integrated into clinical workflow with a minimum of disruption.
MiamiOH OARS

Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium (U54 Clinical Trial Not A... - 0 views

  •  
    The FOA will focus on fusion oncoproteins found in tumors that have high risk of treatment failure and for which there has been little progress in identifying targeted agents. Responsive applications can focus on any fusion oncoprotein in pediatric solid tumors or on NUP98 fusion proteins that occur in young children with acute myelogenous leukemia (AML). However, greater preference will be given to applications focused on PAX-FOXO (alveolar rhabdomyosarcoma), C11orf95RELA (ependymoma), or NUP98 fusion proteins.
MiamiOH OARS

Rivkin Center Accepting Applications for Pilot Studies in Ovarian Cancer Research | RFP... - 0 views

  •  
    Founded in 1996, the Marsha Rivkin Center for Ovarian Cancer Research provides funding for innovative research pilot studies, scholar grants to up-and-coming investigators in ovarian cancer research, early detection screening for ovarian cancer, and nationally and internationally attended research symposia on ovarian cancer.

MiamiOH OARS

Communication and Decision Making for Individuals with Inherited Cancer Syndromes (U01 ... - 0 views

  •  
    This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative (https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative) that is intended to accelerate cancer research. The purpose of this FOA is to develop, test, and evaluate interventions and implementation approaches, or adapt existing approaches, to improve patient/provider/family risk communication and decision making for individuals and families with an inherited susceptibility to cancer. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel/prevention-screening-working-group-report.pdf) Recommendation G (https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel#ui-id-3 ): "Sponsor initiatives to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with cancer development and conduct implementation science research to accelerate development, testing, and broader adoption of proven strategies to significantly reduce cancer risk and address cancer health disparities in these areas." This Funding Opportunity Announcement invites U01 applications for projects that develop, test, and evaluate interventions and implementation approaches, or adapt existing approaches, to improve patient/provider/family risk communication and decision making for individuals and families with an inherited susceptibility to cancer so that they can make informed clinical risk management decisions.
MiamiOH OARS

Prevention of HPV-related Cancers in HIV-infected individuals: United States-Latin Amer... - 0 views

  •  
    The purpose of this Funding Opportunity Announcement (FOA) is to facilitate the design, conduct, and completion of clinical trials for improving prevention of human papillomavirus (HPV)-related cancers in human immunodeficiency virus (HIV)-infected individuals. To serve this goal, the FOA will support a network of international collaborative sites conducting meritorious and appropriately designed prevention clinical trials in the Latin American and Caribbean (LAC) region via a U54 Partnership Centers mechanism.

    Each proposed U54 Partnership Center must be based on a collaboration between a research institution in the United States (as the applicant institution) and partnering institution(s) in low- and middle-income countries (LMICs) in the LAC region. The proposed clinical trials should be focused on optimizing clinical prevention interventions among HIV-infected individuals, including immunoprevention (vaccination), screening and triage, and precancer treatment.

    Each Partnership Center application must propose a Clinical Trials Program that will develop and conduct three prevention clinical trials within the 5-year project period. As infrastructure supporting the Clinical Trials Program, each Partnership Center should include an Administrative and Coordinating Core, a Data Management and Statistical Core, and a Central Laboratory Core. Results of the clinical trials conducted through the Partnership Centers are expected to influence the development of clinical practice guidelines to improve preventive clinical care and reduce the burden of highly preventable HPV-related cancers in HIV-infected individuals.
MiamiOH OARS

Prevention of HPV-related Cancers in HIV-infected individuals: United States-Latin Amer... - 0 views

  •  
    The purpose of this Funding Opportunity Announcement (FOA) is to facilitate the design, conduct, and completion of clinical trials for improving prevention of human papillomavirus (HPV)-related cancers in human immunodeficiency virus (HIV)-infected individuals. To serve this goal, the FOA will support a network of international collaborative sites conducting meritorious and appropriately designed prevention clinical trials in the Latin American and Caribbean (LAC) region via a U54 Partnership Centers mechanism.
MiamiOH OARS

AACR Invites Applications for NextGen Cancer Research Grants | RFPs | PND - 0 views

  •  
    The American Association for Cancer Research is accepting applications for its AACR NextGen Grants for Transformative Cancer Research program.
    The annual program is designed to stimulate highly innovative research from young investigators. To that end, three-year grants of up to $450,000 will be awarded to promote and support creative, paradigm-shifting cancer research unlikely to be funded through conventional channels. The funds are intended to support expenses related to the research project, which may include salary and benefits of the grant recipient, postdoctoral or clinical research fellows, graduate students (including tuition costs), and research assistants, research/laboratory supplies, equipment, travel applicable to the research project, publication charges for manuscripts that pertain directly to the funded project, other research expenses, and indirect costs.

MiamiOH OARS

CCA Issues RFP for Young-Onset Colorectal Cancer Research | RFPs | PND - 0 views

  •  
    Founded in 1999, the Colorectal Cancer Alliance works to empower a nation of advocates to support patients, raise awareness of preventative measures, and inspire efforts to fund critical research. The alliance is committed to investing $10 million in critical research by 2021, including $3 million specifically to young-onset colorectal cancer research.

    To advance this goal, the alliance will award three Colorectal Cancer Alliance Chris4Life Research Grants in Young-Onset Colorectal Cancer Research in December 2018 (funding start date January 2019). Grant proposals will be considered in the categories of basic, translational, clinical, or epidemiological. Projects should focus on risk factors and causes associated with the rise in young-onset colorectal cancer, including but not limited to changes in the microbiome and its impact on young-onset colorectal cancer; prevention and early detection strategies for reducing the incidence and death rates associated with young-onset colorectal cancer; better mechanisms for increasing the long-term survival rates of those with young-onset colorectal cancer; and/or the psychosocial impacts of young-onset colorectal cancer and the overall social influence on daily survivorship.
MiamiOH OARS

RFA-CA-19-004: Pediatric Immunotherapy Discovery and Development Network (PI-DDN)(U01 -... - 0 views

  •  
    This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The overall goal of this FOA and the companion FOA, RFA-CA-19-012, is to establish a network of collaborating investigators to identify and advance research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translation science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system.

MiamiOH OARS

RFA-CA-19-003: Pediatric Immunotherapy Discovery and Development Network (PI-DDN)(U54 -... - 0 views

  •  
    This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to establish centers of collaborating investigators with the goal of identifying and advancing research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translational science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. The Pediatric Immunotherapy Discovery and Development Network (PI-DDN) Centers will address and implement these BRP recommendations.  

MiamiOH OARS

Pediatric Immunotherapy Discovery and Development Network (PI-DDN)(U54 - Clinical Trial... - 0 views

  •  
    This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to establish centers of collaborating investigators with the goal of identifying and advancing research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translational science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. The Pediatric Immunotherapy Discovery and Development Network (PI-DDN) Centers will address and implement these BRP recommendations.
MiamiOH OARS

Approaches to Identify and Care for Individuals with Inherited Cancer Syndromes (U01 Cl... - 0 views

  •  
    This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to increase case ascertainment and appropriate follow-up care, optimizing the delivery of evidence-based healthcare for individuals at high risk of cancer due to an inherited genetic susceptibility. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) Recommendation G: "To realize the potential of cancer prevention and early detection in our nation, NCI should sponsor an initiative to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with cancer development. This initiative should include demonstration projects that will show how cancer screening programs can simultaneously save lives, improve quality of life, and reduce healthcare costs." This Funding Opportunity Announcement (FOA) invites multiple Program Director/Principle Investigator (multi-PD/PI) U01 application for projects aimed at identifying best practices to improve case ascertainment and follow-up care of hereditary cancers, with the goal of improving prevention and detection.
MiamiOH OARS

Approaches to Identify and Care for Individuals with Inherited Cancer Syndromes (U01 Cl... - 0 views

  •  
    This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to increase case ascertainment and appropriate follow-up care, optimizing the delivery of evidence-based healthcare for individuals at high risk of cancer due to an inherited genetic susceptibility.
MiamiOH OARS

Fellowship Announcement | The Matsumae International Foundation - 0 views

  •  
    Eligibility Requirements:
    Applicants of non-Japanese nationality; a Doctorate degree; must be 49 years old or under;  not have been in Japan previously; have firm positions and professions in their home nations; etc.

    Host Institution In Japan:
    Applicants are free to select host institutions (university research laboratories, national research institutions or the corresponding facilities of private industry)

    Fellowship Details:
    Stipend for research and stay, Insurance, Air transportation (a round-trip air ticket to/from Tokyo) and Lump sum on arrival

    Period & Number of Fellowships:
    For a period of from three to six months; the number of fellowships is about 20 persons each year.
1 - 20 of 595 Next › Last »
Showing 20 items per page